Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11668327 | 0.97 | ALDH1A1 (0.63) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 | |
| SCHEMBL29739279 | 0.89 | ALDH1A1 (0.55) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 | |
| SCHEMBL29739439 | 0.89 | POLB (0.56) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 | |
| Phenyl M-Tolylcarbamate SCHEMBL259420 | 0.87 | ALDH1A1 (0.78) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 | |
| Phenyl M-Tolylcarbamate SCHEMBL29739712 | 0.87 | ALDH1A1 (0.78) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 | |
| SCHEMBL29739681 | 0.85 | ALDH1A1 (0.51) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 | |
| SCHEMBL14459621 | 0.85 | CYP1A2 (0.57) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 | |
| SCHEMBL6037499 | 0.84 | ALDH1A1 (0.75) | ALDH1A1MAPTCYP1A2FAAHGAA | |
| SCHEMBL23240069 | 0.83 | ALDH1A1 (0.59) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 | |
| SCHEMBL14459611 | 0.83 | CYP1A2 (0.54) | ALDH1A1MAPTCYP1A2FAAHCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4323350-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-02-15 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022152822-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022152821-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| CN-107417578-A | N (base of 3,5 dimethyladamantane 1) N ' substituted phenylurea compounds and its production and use | 沈阳海诺威医药科技有限公司 | 2017-12-01 | — | — | CN | disclosed |
| EP-1380574-B1 | 9-aminoacridine derivates and process for the preparation thereof | SAMJIN PHARM CO LTD (KR) | 2009-05-20 | — | — | EP | disclosed |
| EP-1380574-A1 | 9-aminoacridine derivates and process for the preparation thereof | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-01-14 | — | — | EP | disclosed |
| US-6620936-B2 | Antitumor agents, topoisomerase inhibitors, notoxic | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2002-08-15 | — | — | US | disclosed |
| EP-1062207-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000037447-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885MAPT 4795/4885CYP1A2 146/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885MAPT 4795/4885CYP1A2 146/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | ALDH1A1 4150/4885MAPT 4671/4885CYP1A2 1677/4885 |
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | ALKBH1, ADCY9, CCR9 | ALDH1A1 97/4885MAPT 4812/4885CYP1A2 1335/4885 |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | ALDH1A1 4088/4885MAPT 3269/4885CYP1A2 4774/4885 |
| US-20240051936-A1 | ISOINDOLINONE COMPOUNDS | CRBN, CDR2, POU2F2 | ALDH1A1 1907/4885MAPT 4743/4885CYP1A2 498/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ALDH1A1 1142/4885MAPT 4795/4885CYP1A2 146/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | ALDH1A1 4276/4885MAPT 3196/4885CYP1A2 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.